Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Rhea-AI Summary

Crescent Biopharma (Nasdaq: CBIO) management will present in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York on Thursday, February 12, 2026 at 11:30 a.m. ET. A live webcast will be available in the Investors section and a replay will be accessible for 90 days.

News Market Reaction

-3.09%

1 alert

-3.09% News Effect

On the day this news was published, CBIO declined 3.09%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Summit date: February 12, 2026 Presentation time: 11:30 a.m. ET Webcast replay period: 90 days

3 metrics

Summit date February 12, 2026 Scheduled Guggenheim Emerging Outlook: Biotech Summit 2026 appearance

Presentation time 11:30 a.m. ET Time of fireside chat at Guggenheim Biotech Summit

Webcast replay period 90 days Replay availability in Investors section of company website

Market Reality Check

Price: $9.51 Vol: Volume 510,788 vs 20-day ...

high vol

$9.51 Last Close

Volume Volume 510,788 vs 20-day average 197,830, showing elevated trading interest ahead of the event. high

Technical Price $9.71 is trading below the 200-day MA at $10.42 and at the 52-week low.

Peers on Argus

CBIO’s move of 1.78% compares with mixed peer action: KYTX -9.29%, NVCT -0.59%, ...

CBIO’s move of 1.78% compares with mixed peer action: KYTX -9.29%, NVCT -0.59%, NTHI +3.41%, CRBU +1.89%, IPHA +1.14%, suggesting stock-specific factors rather than a unified biotech move.

Historical Context

5 past events · Latest: Jan 30 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 30	Inducement option grants	Neutral	+2.4%	Equity option awards to new employees under inducement plan with standard terms.
Jan 05	IND clearances	Positive	+0.3%	U.S. and China regulatory clearances for CR-001 and CR-003 solid tumor programs.
Dec 18	Inducement option grants	Neutral	-3.0%	Employee option grants with 10-year term and vesting, seen with negative price move.
Dec 04	Financing & partnership	Positive	-4.2%	Kelun-Biotech partnership and <b>$185M</b> private placement to fund global pipeline.
Dec 04	Strategic partnership	Positive	-4.2%	Strategic oncology collaboration with Kelun-Biotech on CR-001 and SKB105 programs.

Pattern Detected

Recent positive strategic and clinical news often met with mixed or negative reactions, while routine equity grants have produced small, mixed moves.

Recent Company History

Over the last few months, Crescent Biopharma has reported multiple strategic and financing milestones. On Dec 4, 2025, it announced a transformational Kelun-Biotech partnership and related $185 million private placement, followed by detailed partnership terms the same day, both seeing negative price reactions. Subsequent inducement award grants on Dec 18, 2025 and Jan 30, 2026 led to modest moves. On Jan 5, 2026, regulatory clearances for CR-001 and CR-003 generated only a small positive reaction, showing a cautious market response to news.

Market Pulse Summary

This announcement highlights Crescent Biopharma’s planned participation in the Guggenheim Emerging O...

Analysis

This announcement highlights Crescent Biopharma’s planned participation in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026, offering additional visibility to its oncology pipeline. The webcast and 90-day replay provide broad access for investors to hear management’s messaging. In the months prior, Crescent reported major partnership, financing, and IND clearance milestones, so investors may watch this event for any incremental commentary on timing and execution of these previously disclosed plans.

AI-generated analysis. Not financial advice.

WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York on Thursday, February 12, 2026 at 11:30 a.m. ET.

A live webcast of the presentation will be available in the Investors section of the Company's website at https://investors.crescentbiopharma.com/events-presentations, and a replay will be accessible for 90 days following the event.

About Crescent Biopharma

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.

Contact:

Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586

FAQ

When will Crescent Biopharma (CBIO) present at the Guggenheim Biotech Summit 2026?

Crescent Biopharma will present on February 12, 2026 at 11:30 a.m. ET. According to the company, management will participate in a fireside chat during the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York, offering investor-focused remarks and Q&A.

How can investors watch Crescent Biopharma's (CBIO) webcast on February 12, 2026?

Investors can watch a live webcast via the company's Investors page at the provided events and presentations link. According to the company, the webcast will stream live and a replay will be posted for on-demand viewing for 90 days after the event.

Will Crescent Biopharma (CBIO) provide a replay of the Guggenheim presentation and for how long?

Yes, a replay will be available for 90 days following the event. According to the company, the replay will be accessible in the Investors section of the website for on-demand review after the live fireside chat concludes.

What topics will Crescent Biopharma (CBIO) cover in the Guggenheim fireside chat on Feb 12, 2026?

The company announced management will speak on its clinical-stage programs and strategy during the fireside chat. According to the company, remarks will focus on development progress and corporate outlook relevant to investors and analysts attending the summit.

Where is the Guggenheim Emerging Outlook: Biotech Summit 2026 presentation location for Crescent Biopharma (CBIO)?

The in-person presentation takes place in New York at the Guggenheim Emerging Outlook: Biotech Summit 2026. According to the company, management will appear on stage for a fireside chat and the session will also be webcast for remote investors.